Nektar(US:NKTR) Businesswire·2026-03-16 16:07Core Viewpoint - A class action lawsuit has been filed against Nektar Therapeutics (NKTR) on behalf of shareholders who acquired securities between February 26, 2025, and December 15, 2025, due to alleged securities fraud [1]. Group 1: Lawsuit Details - The lawsuit claims that Nektar made materially false and misleading statements and failed to disclose adverse facts about its business and operations during the class period [4]. - Specifically, it is alleged that the enrollment in the REZOLVE-AA trial did not adhere to applicable instructions and protocols, which negatively impacted the trial's results [4]. - Following the announcement of the trial's failure to reach statistical significance on December 16, 2025, Nektar's stock price dropped by $4.14, or 7.8%, closing at $49.16 per share [3]. Group 2: Shareholder Actions - Shareholders who suffered losses on their Nektar investments are encouraged to inquire about participating in the ongoing securities fraud lawsuit [2]. - The deadline for filing a lead plaintiff motion is set for May 5, 2026 [1].